At TCT, Cardiology Companies Invade Neurology's Turf
Executive Summary
Having gradually chipped away at the patient base of surgeons, where are interventional cardiologists to go next? One answer: neurology. At this year's TCT meeting, two new areas of stroke prevention were discussed as potential growth opportunities. The first area is PFO closure: 25% of people in the general population have a congenital heart wall defect that is associated with cryptogenic stroke. In the other, left atrial appendage occlusion, to eliminate a pouch in the heart that can collect clots that cause stroke in patients with atrial fibrillation.
You may also be interested in...
TCT Highlights: Late Stent Thrombosis Controversy Continues
Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).
A Little Light Shines On Interventional Neuroradiologists
The young and hybrid specialty of interventional neuroradiology is pushing to assume a leadership role in treatment of acute neurovascular disease. Interventional neuroradiologists are the endovascular experts who attempt to do for the brain what interventional cardiologists do for the heart. Their success has ijmplications for device companies, which are eyeing the field but hesitant to commit heavily to it because of concerns about market size and infrastructure.
A Little Light Shines On Interventional Neuroradiologists
The young and hybrid specialty of interventional neuroradiology is pushing to assume a leadership role in treatment of acute neurovascular disease. Interventional neuroradiologists are the endovascular experts who attempt to do for the brain what interventional cardiologists do for the heart. Their success has ijmplications for device companies, which are eyeing the field but hesitant to commit heavily to it because of concerns about market size and infrastructure.